Business Context and Reporting Period
Company: James Hardie Industries plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Date: December 14, 2018
Context: This filing serves as a notification of changes to the General Management Team, as detailed in Exhibit 99.1. The document does not contain financial results or operational data for a specific fiscal period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing regarding management changes and does not include financial statements or performance metrics.
Material Changes
Management Changes: The primary material event disclosed is a change to the General Management Team, referenced in Exhibit 99.1. Specific details regarding the individuals involved or the nature of the restructuring are not included in the provided text.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing includes a comprehensive disclaimer regarding forward-looking statements. These statements cover future performance, capital expenditure projects, credit facility renewals, dividend payments, and share buy-backs.
Key Risks Identified:
- Liabilities related to prior asbestos product manufacture and contributions to the Asbestos Injuries Compensation Fund (AICF).
- Currency exchange rate fluctuations affecting financial statements.
- Changes in tax laws and treatments.
- Competition, product pricing, and potential product failures.
- Legal proceedings, including environmental and consumer class actions.
- General economic conditions, housing market trends, and raw material costs.
- Integration of Fermacell into the business.
Investor Verification Checklist
- Review Exhibit 99.1 (Announcement of Changes to General Management Team) for specific details on personnel changes.
- Verify the impact of management changes on strategic direction and operational continuity.
- Monitor updates regarding the Asbestos Injuries Compensation Fund (AICF) and associated liabilities.
- Check subsequent filings (Form 20-F or quarterly reports) for actual financial performance data not included here.
- Assess the status of the Fermacell integration as noted in the risk factors.